NDA No.	Drug	Applicant
6–615	Veto Cream Deodorant	Colgate-Palmolive Co., P.O. Box 1343, 909 River Rd., Piscataway, NJ 08855–1343.
7–871	Perazil Cream	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.
8–842	Raudixin Tablets	Apothecon, Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543–4500.
10–653	Disipal Tablets	Riker Laboratories Inc., 3M Pharmaceuticals, 270–3A–01 3M Center, St. Paul, MN 55144–1000.
12–026	Apresoline-Esidrix Tablets	Ciba Pharmaceuticals Division, Ciba-Geigy Corp., 556 Morris Ave., Summit, NJ 07901–1398.
12–402	Ivadantin Injection	Procter & Gamble Pharmaceuticals, Regulatory and Clinical Development, Sharon Woods Technical Center, 11370 Reed Hartman Hwy., Cincinnati, OH 45241–2422.
16–069	Mepriam Tablets	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.
16–379	Locorten Cream	Ciba Pharmaceuticals Division.
17–046	Kaon-Cl/Koan-Cl 10 Tablets	Savage Laboratories, Division of Altana Inc., 60 Baylis Rd., Melville, NY 11747.
17–244	Uticort Gel	Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105.
17–739	Monistat-Derm Lotion	The R.W. Johnson Pharmaceutical Research Institute, Route 202, P.O. Box 300, Raritan, NJ 08869–0602.
17–941	Sudafed 12–Hour Capsules	Burroughs Wellcome Co.
18–004	Hydroxyprogesterone Caproate Injection	Akorn Inc., P.O. Box 1220, Decatur, IL 62525.
18–009	Sarenin Injection	Procter & Gamble Pharmaceuticals.
18–075	K-TimeKap Capsules	Ciba Pharmaceuticals Division.
18–166	Trasicor Capsules	Do.
18–816	Micatin Antifungal Powder	Advanced Care Products, Ortho Pharmaceutical Corp., J&J Research Complex, Route 1 South and Middleton Rd., North Brunswick, NJ 08902–0724.
18–872	Viskazide Tablets	Sandoz Pharmaceuticals Corp., 59 Route 10, East Hanover, NJ 07936–1080.
19–208	Actifed Capsules	Burroughs Wellcome Co.
19–451	Lopressor Chlorthalidone Capsules	Ciba Pharmaceutials Division.
20–158	Deracyn Tablets	The Upjohn Co., U.S. Pharmaceutical Regulatory Affairs, 7000 Portage Rd., Kalamazoo, MI 49001–0199.
50–473	Velosef Powder for Oral Suspension	Apothecon.
50–474	Velosef Capsules	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 21, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95–24158 Filed 9–28–95; 8:45 am]

BILLING CODE 4160–01–P

[Docket No. 95N–0319]

Roche Pharmaceutical Inc., et al.; Withdrawal of Approval of 13 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 13 new drug applications (NDA's). The holders of the NDA's notified the agency in writing that the drug products were no longer being marketed under the NDA and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: September 29, 1995.

FOR FURTHER INFORMATION CONTACT: Nancy Maizel, Center for Drug Evaluation and Research (HFD–53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2623.

SUPPLEMENTARY INFORMATION: The holders of the NDA's listed below have informed FDA that these drug products are no longer being marketed under the NDA and requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

NDA No.	Drug	Applicant
8–414	Gantrisin Ophthalmic Ointment	Roche Pharmaceuticals, Division of Hoffmann-La Roche Inc., 340 Kingsland St., Nutley, NJ 07110–1199.
18–996	Actifed 12–Hour Capsules	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.
50–102	Dynapen for Injection	Apothecon, Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543–4500.
50–117	Staphcillin Injection	Do.
50–118	Prostaphlin Capsules	Do.
50–167	Polysporin Aerosol Spray	Burroughs Wellcome Co.
50–176	Neosporin Cream	Do.
50–191	Tegopen Capsules	Apothecon.

NDA No.	Drug	Applicant
50–192	Tegopen Powder for Oral Solution	Do.
50–194	Prostaphlin Powder for Oral Solution	Do.
50–195	Prostaphlin (Oxacillin Sodium) for Injection	Apothecon.
50–308	Polycillin (Ampicillin) Powder for Oral Solution	Do.
50–337	Dynapen for Oral Suspension	Do.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director of the Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 21, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95–24156 Filed 9–28–95; 8:45 am]

BILLING CODE 4160–01–P

[Docket No. 95N–0318]

Searle, et al.; Withdrawal of Approval of 17 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 17 new drug applications (NDA's). The holders of the NDA's notified the agency in writing that the drug products were no longer being marketed under the NDA and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: September 29, 1995.

FOR FURTHER INFORMATION CONTACT: Nancy G. Maizel, Center for Drug Evaluation and Research (HFD–53), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2623.

SUPPLEMENTARY INFORMATION: The holders of the NDA's listed below have informed FDA that these drug products are no longer being marketed under the NDA and have requested that FDA withdraw approval of the applications. The applicants have also, by request, waived their opportunity for a hearing.

NDA No.	Drug	Applicant
2–386	Aminophyllin Tablets	Searle, 4901 Searle Pkwy., Skokie, IL 60077
3–205	Pantholin Tablets	Lilly Research Laboratories, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285.
6–917	Gantrisin Injection	Hoffmann-La Roche Inc., Roche Pharmaceuticals, 340 Kingsland St., Nutley, NJ 07110–1199.
8–867	Rauwiloid Tablets	3M Pharmaceuticals, 3M Center, St. Paul, MN 55144–1000.
9–078	Parsidol Tablets	Parke-Davis Pharmaceutical Research, 2800 Plymouth Rd., Ann Arbor, MI 48105.
9–299	Hyperloid Tablets	Person & Covey Inc., P.O. Box 25018, 616 Allen Ave., Glendale, CA 91221–5018.
11–045	Milprem Tablets	Wallace Laboratories, Division of Carter-Wallace Inc., 301B College Rd. East, Princeton, NJ 08540.
11–110	Actidil Tablets	Burroughs Wellcome Co., 3030 Cornwallis Rd., P.O. Box 12700, Research Triangle Park, NC 27709–2700.
11–496	Actidil Syrup	Do.
11–535	Equanil Meprobamate Suspension	Wyeth-Ayerst Laboratories, P.O. Box 8299, Philadelphia, PA 19101–8299.
11–876	Fedrazil Tablets	Burroughs Wellcome Co.
17–528	Uticort Lotion	Parke-Davis Pharmaceutical Research.
17–917	Duraquin Tablets	Warner Chilcott Laboratories, 201 Tabor Rd., Morris Plains, NJ 07950.
18–375	Turgex Bacteriostatic Skin Cleanser (Aerosol)	Xttrium Laboratories Inc., 415 West Pershing Rd., Chicago, IL 60609.
19–055	Turgex Bacteriostatic Skin Cleanser (Emulsion)	Do.
50–019	Penbritin Ampicillin Drops	Wyeth-Ayerst Laboratories.
50–355	Coly-Mycin S Oral Suspension	Parke-Davis Pharmaceutical Research.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the NDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective September 29, 1995.

Dated: September 2, 1995.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 95–24157 Filed 9–28–95; 8:45 am]

BILLING CODE 4160–01–P

Advisory Committees; Notice of Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces forthcoming meetings of public advisory committees of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meetings and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone